722 related articles for article (PubMed ID: 27843050)
1. Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life.
Becattini C; Franco L; Beyer-Westendorf J; Masotti L; Nitti C; Vanni S; Manina G; Cattinelli S; Cappelli R; Sbrojavacca R; Pomero F; Marten S; Agnelli G
Int J Cardiol; 2017 Jan; 227():261-266. PubMed ID: 27843050
[TBL] [Abstract][Full Text] [Related]
2. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
3. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
[TBL] [Abstract][Full Text] [Related]
4. Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation.
Raposeiras-Roubín S; Alonso Rodríguez D; Camacho Freire SJ; Abu-Assi E; Cobas-Paz R; Rodríguez Pascual C; García Comesaña J; González-Carrero López A; Cubelos Fernández N; López-Masjuán Ríos Á; Cespón-Fernández M; Muñoz-Pousa I; Caneiro-Queija B; Rodríguez Albarrán A; Castañera SÁ; Guillén JV; Carpintero Vara A; Barreiro Pardal C; Domínguez-Erquicia P; Domínguez-Rodríguez LM; Díaz Fernández JF; Fernández Vázquez F; Iñíguez-Romo A
J Am Med Dir Assoc; 2020 Mar; 21(3):367-373.e1. PubMed ID: 31753740
[TBL] [Abstract][Full Text] [Related]
5. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
[TBL] [Abstract][Full Text] [Related]
6. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
[TBL] [Abstract][Full Text] [Related]
7. An Evidence-Based Approach to Anticoagulation Therapy Comparing Direct Oral Anticoagulants and Vitamin K Antagonists in Patients With Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review, Meta-Analysis, and Network Meta-Analysis.
Suppah M; Kamal A; Saadoun R; Baradeiya AMA; Abraham B; Alsidawi S; Sorajja D; Fortuin FD; Arsanjani R
Am J Cardiol; 2023 Nov; 206():132-150. PubMed ID: 37703679
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
[TBL] [Abstract][Full Text] [Related]
9. Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants.
Ashley J; McArthur E; Bota S; Harel Z; Battistella M; Molnar AO; Jun M; Badve SV; Garg AX; Manuel D; Tanuseputro P; Wells P; Mavrakanas T; Rhodes E; Sood MM
Am J Kidney Dis; 2020 Sep; 76(3):311-320. PubMed ID: 32333946
[TBL] [Abstract][Full Text] [Related]
10. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review.
Wu C; Alotaibi GS; Alsaleh K; Sean McMurtry M
Thromb Res; 2014 Sep; 134(3):627-32. PubMed ID: 25047174
[TBL] [Abstract][Full Text] [Related]
11. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Zirlik A; Bode C
J Thromb Thrombolysis; 2017 Apr; 43(3):365-379. PubMed ID: 27896543
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies.
Archontakis-Barakakis P; Li W; Kalaitzoglou D; Tzelves L; Manolopoulos A; Giannopoulos S; Giamouzis G; Giannakoulas G; Batsidis A; Palaiodimos L; Ntaios G; Lip GYH; Kokkinidis DG
Br J Clin Pharmacol; 2022 Nov; 88(11):4663-4675. PubMed ID: 35853612
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Traumatic Intracranial Hemorrhage Expansion and Outcomes Among Patients on Direct Oral Anticoagulants Versus Vitamin k Antagonists.
Shin SS; Marsh EB; Ali H; Nyquist PA; Hanley DF; Ziai WC
Neurocrit Care; 2020 Apr; 32(2):407-418. PubMed ID: 32034657
[TBL] [Abstract][Full Text] [Related]
14. Significant Benefit of Uninterrupted DOACs Versus VKA During Catheter Ablation of Atrial Fibrillation.
Romero J; Cerrud-Rodriguez RC; Alviz I; Diaz JC; Rodriguez D; Arshad S; Cerna L; Taveras J; Grupposo V; Natale A; Garcia M; Di Biase L
JACC Clin Electrophysiol; 2019 Dec; 5(12):1396-1405. PubMed ID: 31857038
[TBL] [Abstract][Full Text] [Related]
15. Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study.
Paschke LM; Klimke K; Altiner A; von Stillfried D; Schulz M
BMC Med; 2020 Aug; 18(1):254. PubMed ID: 32847578
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
17. Risks of postextraction bleeding after receiving direct oral anticoagulants or warfarin: a retrospective cohort study.
Yagyuu T; Kawakami M; Ueyama Y; Imada M; Kurihara M; Matsusue Y; Imai Y; Yamamoto K; Kirita T
BMJ Open; 2017 Aug; 7(8):e015952. PubMed ID: 28827248
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation - a network meta-analysis of real-world data.
Hirschl M; Kundi M
Vasa; 2019 Mar; 48(2):134-147. PubMed ID: 30376416
[TBL] [Abstract][Full Text] [Related]
19. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis.
Mariani MV; Magnocavallo M; Straito M; Piro A; Severino P; Iannucci G; Chimenti C; Mancone M; Rocca DGD; Forleo GB; Fedele F; Lavalle C
J Thromb Thrombolysis; 2021 Feb; 51(2):419-429. PubMed ID: 33044735
[TBL] [Abstract][Full Text] [Related]
20. Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation.
Souverein PC; van den Ham HA; Huerta C; Merino EM; Montero D; León-Muñoz LM; Schmiedl S; Heeke A; Rottenkolber M; Andersen M; Aakjaer M; De Bruin ML; Klungel OH; Gardarsdottir H
Br J Clin Pharmacol; 2021 Mar; 87(3):988-1000. PubMed ID: 32627222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]